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Background: Southeast Asia has been identified as a potential epicentre of emerging diseases with pandemic
capacity, including highly pathogenic influenza. Cambodia in particular has the potential for high rates of avoidable
deaths from pandemic influenza due to large gaps in health system resources. This study seeks to better
understand the course and cost-of-illness for cases of highly pathogenic avian influenza in Cambodia.
Methods: We studied the 18 laboratory-confirmed cases of avian influenza subtype H5N1 identified in Cambodia
between January 2005 and August 2011. Medical records for all patients were reviewed to extract information on
patient characteristics, travel to hospital, time to admission, diagnostic testing, treatment and disease outcomes.
Further data related to costs was collected through interviews with key informants at district and provincial
hospitals, the Ministry of Health and non-governmental organisations. An ingredient-based approach was used to
estimate the total economic cost for each study patient. Costing was conducted from a societal perspective and
included both financial and opportunity costs to the patient or carer. Sensitivity analysis was undertaken to evaluate
potential change or variation in the cost-of-illness.
Results: Of the 18 patients studied, 11 (61%) were under the age of 18 years. The majority of patients (16, 89%)
died, eight (44%) within 24 hours of hospital admission. There was an average delay of seven days between
symptom onset and hospitalisation with patients travelling an average of 148 kilometres (8-476 km) to the
admitting hospital. Five patients were treated with oseltamivir of whom two received the recommended dose. For
the 16 patients who received all their treatment in Cambodia the average per patient cost of H5N1 influenza illness
was US$300 of which 85.0% comprised direct medical provider costs, including diagnostic testing (41.2%),
pharmaceuticals (28.4%), hospitalisation (10.4%), oxygen (4.4%) and outpatient consultations (0.6%). Patient or family
costs were US$45 per patient (15.0%) of total economic cost.
Conclusion: Cases of avian influenza in Cambodia were characterised by delays in hospitalisation, deficiencies in
some aspects of treatment and a high fatality rate. The costs associated with medical care, particularly diagnostic
testing and pharmaceutical therapy, were major contributors to the relatively high cost-of-illness.
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A future influenza pandemic has the potential to cause
millions of deaths and significantly impact on the global
economy [1]. Southeast Asia has been identified by the
World Health Organisation (WHO) as being at risk for
emerging diseases including avian influenza [2]. There* Correspondence: karen@cdprg.org
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distribution, and reproduction in any mediumhave been a number of cases of highly pathogenic avian
influenza (HPAI) subtype H5N1 in the region which has
had a serious impact on the poultry industry and associated
livelihoods [3,4]. Whilst mortality in domestic poultry has
been very high, it is the potential to cause serious disease
in humans and the subsequent risk of pandemic spread
that causes particular concern [4]. For many patients,
HPAI infections follow an unusually aggressive clinical
course, with rapid deterioration and high fatality [4,5].
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72% of the deaths have been in the Southeast Asia [6].
A number of factors contribute to Southeast Asia’s
vulnerability to infectious diseases including population
growth and movement, urbanisation, environmental factors
such as agriculture, land use, water and sanitation,
health system factors and the development of drug
resistance [3]. The close contact between animals and
humans, particularly in rural settings also enhances the
vulnerability for outbreaks of zoonotic infections such
as HPAI [3]. Countries with the lowest income will suffer
the greatest burden from disease [3]. Cambodia is one
of the poorest countries in Southeast Asia ranking 138th
on the United Nations Development Program Human
Development Index [7]. Data from the WHO Burden of
Disease, confirms the burden of communicable disease
weighs more heavily on Cambodia than other countries
within the region [8].
The WHO has expressed concern regarding the inad-
equacy of global preparedness for an influenza pandemic
[3]. Cambodia, like many other developing countries,
has a limited and likely insufficient level of pandemic
preparedness to deal with an outbreak of a highly patho-
genic and transmissible strain of influenza [3,9-12]. Based
on data collected regarding key health system resources,
Cambodia has been identified as having some of the
largest resource gaps and potentially the highest rate of
avoidable deaths when compared to other countries in
Southeast Asia, including Indonesia, Lao PDR, Taiwan,
Thailand and Vietnam [12]. Cambodia has the lowest
density of health professionals per capita in the region;
insufficient healthcare facilities with no surge capacity;
equipment shortages including mechanical ventilators;
and only 0.025% of the WHO recommended national
stock of anti-viral tablets [3,9-12; Sok Touch, Ministry of
Health Cambodia, personal communication]. Additionally
Cambodia does not have any discretionary budget for
local level administration for influenza or pandemic
preparation [10]. To address these issues, the Royal
Government of Cambodia has developed a comprehensive
multi-sectoral pandemic preparedness plan [13].
An influenza pandemic may not only result in significant
loss of life but also have a substantial impact on the
economy. The 2003 SARS outbreak demonstrated that
even a disease with relatively limited health impacts can
have a major effect on the economy of a region [14].
The Asian Development Bank estimate the impact of
SARS in East Asia was approximately US$18 billion and
suggest that an influenza pandemic could be substantially
more [14]. Compared to SARS, HPAI has not significantly
impacted tourism however it has been extremely damaging
to the poultry industry [3,14]. The cost to the poultry sector
in Cambodia, Thailand and Vietnam has been estimated
at US$560 million [14]. Smallholder farmers dependenton poultry production are more likely to have difficulty
in overcoming the costs of culling and restocking [15].
Backyard systems of poultry farming have traditionally
dominated the industry in Cambodia with close proximity
of fowl in villages or backyards, minimal biosecurity and
local consumption [15]. Those living or working closely
with poultry are more at risk of contracting HPAI and
incurring illness-related costs. Unfortunately it is the poor
who are particularly at risk of the zoonoses associated
with livestock keeping; they are also those least able to
afford the cost-of-illness (COI), the resources expended or
foregone as a result of disease [3,16]. There has been no
research published regarding the COI for HPAI in the
Southeast Asia. This study seeks to determine the COI in
Cambodia, one of the most vulnerable countries in that
region.
At the end of 2011, eighteen laboratory-confirmed
cases of H5N1 had been reported in Cambodia [6]. Here
we present details of these cases, estimate the COI and
compare these findings, where possible, with others
reported from the region. We do so with the aim of
better understanding the course of HPAI in Cambodia
and to provide a foundation on which to develop recom-
mendations for policies and plans to facilitate pandemic
mitigation.
Methods
All cases included in this study were identified between
January 2005 and August 2011 and confirmed as positive
for the H5N1 virus using the polymerase chain reaction
(PCR) test by the laboratories of the Institut Pasteur, in
either Phnom Penh or Ho Chi Minh. These cases had
then been reported to the Centre for Communicable
Diseases in the Cambodian Ministry of Health (MOH),
Phnom Penh. Data for these patients was collected, with
permission from the MOH, through review of medical
records and interviews with staff at the admitting hospitals
during a field visit in December 2011. A general study
consent form was utilised for in-depth interviews. Verbal
assent was used in place of written consent for information
gathered in the hospital setting from shorter, less formal
interactions.
This study takes a societal perspective regarding the
cost-of-illness for HPAI, meaning indirect costs to patients
and their families are included in addition to medical
provider costs [17]. This approach was taken in order to
determine the full economic cost of illness. Data collection
utilised an ingredients approach with micro-costing of
key elements [17]. Costs were gathered in or converted,
where necessary, to US dollars [18]. Whilst all reported
patients originated in Cambodia and were reported to
the Cambodian MOH, two patients were hospitalised in
Vietnam. These cases were excluded from the cost-of-illness
analysis since data, regarding some aspects of care and the
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by inflation or deflation to 2011 parity using inflation
rates cited by the International Monetary Fund and the
Cambodian National Institute of Statistics [19,20]. The
medical provider cost centres used in analysis were out-
patient consultations, inpatient facility costs including
capital and personnel costs, pharmaceuticals, diagnostic
tests and oxygen administration. Diagnostic tests included
viral PCR, anti-viral phenotypic testing, full blood counts,
renal function tests (urea, creatinine, and other electrolytes),
liver function tests, acute phase proteins as well as urine
dipstick tests. The costs of full genomic sequencing of the
viral strain and tests to detect antigenic drift were not
included as these were assumed to be research related.
The pharmaceuticals utilised were categorised as antivirals,
antibiotics, antipyretics, corticosteroids or other medication.
The costs centres attributed to the patient or family
included travel expenses to the hospital of admission,
food whilst hospitalised and the indirect cost of loss of
income for the patient or caregiver due to hospitalisation.
Information on treatment costs recovered from patients
or organisations paying user fees on behalf of the patients
was not available.
WHO country specific unit costs, adjusted for inflation,
were utilised in accounting for outpatient consultations at
rural health services, public health centres, physicians’
clinics and nurse visits [21]. Other costs were determined
from data gathered in April-June 2012 from the Institut
Pasteur, Ministry of Health, retail pharmacies and inter-
views with physicians and staff at hospitals in Kampot
and Angkor Chey. In general, outpatient consultations
and hospitalisation are represented by actual costs
where as charges are utilised for pharmaceuticals and
diagnostic tests due to the lack of cost data at the time
of writing. Retail pharmacy pricing was utilised when
data was unavailable from hospital visits. A recent
study, commissioned by University Research Company
assessing hospital costing and financial management,
provided hospitalisation costs per bed day, excluding in
kind drugs [22]. The values reported for bed per day are
very similar to those cited by WHO data (adjusted for
inflation) with a hospitalisation cost per day of $8 to
$10 [22] compared to $7 to $9 [21]. Travel costs to the
admitting hospital were derived using the University
Research Co. model which takes into account not only
distance travelled but also the quality of the roads
[T Jordanwood, University Research Co., LLC, Cambodia,
personal communication]. With regard to lost income,
this was calculated using a human-capital approach as a
combination of both patient and caregiver earnings. It
was assumed, based on employment statistics from the
Cambodian National Institute of Statistics (NIS), that
74% of all caregivers and patients over the age of 18
years would be employed but only 20% of those agedbetween 6–18 years and no children under the age of six
years [20]. It was also assumed that all children under the
age of 6 years required the presence of a full-time
caregiver; 50% of those aged 6–18 years had a caregiver
present; and that no caregiver was present for those over
the age of 18 years. Average income was based on NIS
data and adjusted for inflation to US$237 per month, for a
six day working week [20].
A multi-variate sensitivity analysis was performed
using the average cost of the case series as the baseline
cost-of-illness. Upper and lower scenarios were developed
for the patient care in order to determine the impact on
the COI cost centres. The minimal care comparator was
outpatient care only, including a single consultation and
the average cost of outpatient medication whilst the
maximum utilised the full battery of diagnostics and
treatment, including a complete adult course of oseltamivir
and higher cost hospitalisation in an intensive care
unit [22].
Ethics approval was obtained from the Cambodian
National Ethics Committee for Health Research and
London School of Hygiene and Tropical Medicine.Results
Six hospitals reported laboratory confirmed cases of H5N1
originating in Cambodia: the Kantha Bopha Children’s
Hospitals in Phnom Penh and Siem Reap (six and four
patients respectively), the Calmette Hospital in Phnom
Penh (four patients), the Kieng Gieng Hospital in
Vietnam (two patients), the Kampong Cham Regional
Hospital (one patient), and the ‘Cambodia-Japan Friendship’
Mongkul Borie Provincial Hospital in Banteay Meanchey
Province (one patient). The median age of those reported
with H5N1 was 10.5 years (mean: 14.7 years, range: 11
months - 57 years) with the majority (11 of 18 patients,
61%) being under the age of 18 years. Twelve of the
patients (67%) were female. There was a median delay of 7
days (mean: 7.3 days, range: 3–26 days) between symptom
onset and hospitalisation and six days (mean: 6.2 days,
range: 2 - 13 days) between initial outpatient treatment
and viral testing. Sampling for the PCR test used in
the diagnosis of the H5N1 virus was performed by the
admitting hospitals with analysis carried out by the
Institut Pasteur. Five patients were treated with
oseltamivir of whom only two adults received the
recommended dose of two capsules per day for five
days. The remaining three child patients died before
they could receive a full course of the anti-viral. Time
from onset of symptoms to treatment with oseltamivir
was a median of 9 days (mean: 12.0 days, range: 5 - 26
days). Children five years and younger were admitted a
mean 5.7 days following symptom onset, whilst adults 18
years and older were hospitalised after 9.7 days. No
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recommended 48 hours from the onset of symptoms.
Many patients, travelled substantial distances to be
admitted into hospital (mean distance of travel 167 km,
range 8-476 km). Only two patients, those hospitalised
in Vietnam, received invasive ventilation. An average of
four antibiotics (range: 1 - 7) were used in the treatment
of patients, with one third of patients receiving five or
more. Ten patients (56%) received corticosteroid treatment.
Sixteen of the 18 patients died giving a particularly high
case fatality rate of 89%. Eight of the 16 patients, for
whom data is available, died within 24 hours of admission
to hospital. The most common cause of death was
multi-organ failure or acute respiratory distress syndrome,
precipitated by pneumonia and sepsis. The two surviving
patients both received a full course of oseltamivir and
were aged 19 years and 57 years.
Cost-of-illness
The cost-of-illness was calculated for the 16 patients
who received their care in Cambodia; the two patients who
travelled to Vietnam for hospitalisation were excluded due
to lack of data. The average cost-of-illness for H5N1 HPAI
(2005 - 2011) was US$299.69 per patient of which 85.0%
comprised medical provider costs. The components of the
cost-of-illness are shown in Table 1. Of the medical costsTable 1 The cost-of-illness for patients diagnosed and hospita








1 1.41 30.00 11.74 135.47 112.56
2 2.82 10.00 3.91 113.43 119.50
3 1.41 40.00 15.65 109.67 355.16
4 1.41 40.00 15.65 116.65 57.41
5 1.41 8.00 3.91 82.15 37.18
6 1.41 80.00 31.30 124.53 129.92
7 1.41 10.00 3.91 101.08 33.69
8 1.41 10.00 3.91 125.18 19.74
9 1.41 72.00 35.21 88.18 30.61
10 2.82 80.00 39.12 183.17 109.64
11 2.82 20.00 7.82 149.89 50.04
12 1.41 40.00 15.65 115.69 115.01
13 2.82 20.00 7.82 82.15 48.99
14 1.41 20.00 7.82 164.20 63.62
15* 2.82
16 1.41 10.00 3.91 131.21 0.05
17* 2.82
18 2.82 10.00 3.91 151.95 79.32
Mean 1.85 31.25 11.74 123.41 85.15
% of total costs 0.6% 10.4% 4.4% 41.2% 28.4%
* Patients hospitalised in Vietnam were excluded from cost analysis.the greatest contributor was diagnostic testing ($123.41,
41.2%) followed by pharmaceuticals ($85.15, 28.4%),
hospital bed ($31.25, 10.4%), oxygen ($13.20, 4.4%) and
outpatient consultations ($1.85, 0.6%). Of the diagnostic
testing performed it was PCR viral testing that represented
the most significant cost, being 32.2% of medical provider
costs. Antibiotics and other medications made up most of
the pharmaceutical costs being 13.0% and 14.3% of
medical provider costs respectively whilst oseltamivir only
contributed 1.3% due to low usage. Patient or family costs
were estimated to be 15.0% of the cost of illness or
approximately US$44.82 per patient. These costs increase
however to US$55.77 or 18.6% if outpatient medical costs
are included. Lost income and travel costs were the
greatest contributors to family costs, representing $23.54
(52.5%) and $18.88 (42.1%) respectively (Figure 1).
For the two surviving patients the mean total COI was
$397.63 whilst for the remaining patients, all of whom
died, the COI was $285.70. Table 2 shows the results of
the sensitivity analysis for cases receiving maximum and
minimum care. The minimum care scenario, resulted in
a total COI of $10.51, the majority being attributable to
outpatient pharmaceuticals $9.10 (86.6%). The maximum
cost scenario produced a total COI of $835.66, with the
greatest contributors being pharmaceuticals (42.5%),
diagnostic tests (21.9%) and hospitalisation (17.1%). Thelised with H5N1 influenza in Cambodia
Patient and carer costs (US$) Total cost (US$)
aceuticals Total Travel Food Loss of
income
Total
291.62 16.00 2.93 19.48 38.41 330.03
250.09 16.00 0.73 8.25 24.98 275.07
522.41 12.00 3.91 25.97 41.88 564.28
231.64 38.00 3.91 25.97 67.88 299.52
132.92 40.00 0.49 6.49 46.98 179.90
368.03 24.00 5.86 65.97 95.83 463.86
150.35 8.00 0.98 6.49 15.47 165.82
160.51 26.00 0.49 6.49 32.98 193.49
228.37 6.00 4.40 58.43 68.82 297.19
415.98 14.00 4.89 64.92 83.80 499.78
231.09 14.00 1.47 16.49 31.96 263.05
288.28 18.00 3.91 25.97 47.88 336.16
162.31 32.00 1.47 16.49 49.96 212.27
257.40 10.00 1.95 12.98 24.94 282.34
146.84 14.00 0.49 6.49 20.98 167.82
248.43 14.00 0.73 8.25 22.98 271.41
254.87 18.88 2.41 23.54 44.82 299.69
85.0% 6.3% 0.8% 8.3% 15.0% 100%
Figure 1 The contribution of components to the cost-of-illness for H5N1 (% of total cost). This pie chart illustrates the percentage
contribution of the cost components to the total cost-of-illness for H5N1 HPAI in Cambodia. The cost components are divided into medical
provider costs or patient and carer costs. Those costs, which are attributable to the patient or carer are cross-hatched.
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of increased contribution to costs from hospitalisation in
an intensive care unit and pharmaceuticals and the
reduced relative input of diagnostic testing (Figure 2).Discussion
The median delay between the onset of HPAI symptoms
and hospitalisation of seven days was similar to that
reported for other countries in the region, six days in
Indonesia and Vietnam and five days in Thailand
[23-25]. Children aged ≤5 years were hospitalised more
quickly than adults although it still took an average of 5.7
days for children to be admitted. A study of 13 countries
from Asia and the Middle East, also found more prompt
hospitalisation of children ≤5 years [26]. Due to the
reliance on hospitals to manage viral diagnostic testing, it
was instigated a median of six days following initial
treatment. Early identification of suspect cases is important
for receiving prompt and appropriate medical care, which
may improve outcomes and reduce the COI. Rapid
immunoassay tests utilised at the community level may
provide an opportunity to achieve more timely diagnoses.
Notification of local poultry outbreaks may raise theTable 2 Sensitivity analysis of cost-of-illness for patients diag
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(42.5%)suspicion of community health workers, directing viral
testing and treatment with antivirals.
Fewer patients in Cambodia (28%) received antiviral
treatment with oseltamivir, compared to those in
Indonesia (69%), Thailand, (57-71%) and Vietnam (82%)
and for those patients who did receive the drug, time to
treatment was longer for the Cambodian group, (median
nine versus seven days) [23-25]. This delay in antiviral
treatment represents a significant deviation from the
recommended 48 hours [4,5]. Whilst earlier treatment
may be more beneficial, initiation and treatment with
oseltamivir up to 6 - 8 days after symptom onset has
been found to reduce mortality [5,26,27]. No parenteral
or oral solution oseltamivir has been reported to be
available in Cambodia and this may also have been a
barrier to treatment of children. Problems procuring such
formulations have been reported in other low-income
countries, as have difficulties in adjusting doses for young
children [27].
The excessive use of antibiotics in the treatment of
HPAI is of concern considering the potential for the
development of antibiotic resistance amongst bacterial
strains. Corticosteroids were also commonly prescribed,
despite a lack of evidence regarding effectiveness andnosed and hospitalised with H5N1 influenza
Patient costs (% of row total cost) Total cost
US$ (% of average
scenario)































Figure 2 Sensitivity of cost-of-illness for H5N1 to change in intensity of care (% change in total cost). This tornado diagram was derived
from a multi-way sensitivity analysis and illustrates the percentage change in total cost-of-illness when the intensity of care is varied. The baseline
is the average COI from the case series. Upper and lower scenarios were developed for the patient care in order to determine the impact on the
COI cost centres. The minimum care comparator incudes only outpatient consultation and loss of income due to illness whilst the maximum
scenario utilises a full battery of diagnostics and treatment, including a complete adult course of oseltamivir and higher cost of hospitalisation in
an intensive care unit.
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treatment of H5N1 [27]. Finally none of the patients
hospitalised in Cambodia received mechanical ventilation
probably as a result of equipment shortages which have
been reported in all provinces [12]. The WHO recommend
investment in oxygen systems to improve the diagnosis
and management of hypoxaemia as part of health system
support for the clinical management of influenza [27].
Hypoxaemia is a common and major cause of mortality
in those patients suffering pneumonia and a lack of
mechanical ventilators is likely to contribute significantly
to avoidable deaths [12,27].
The case fatality rate of 89% for patients diagnosed
with HPAI in Cambodia to the end of 2011 is notably
higher than the rate of 58.7% reported globally [6]. It is
also higher than other case fatality rates (CFR) reported
in Southeast Asia, (Vietnam 50%, Thailand 68% and
Indonesia 82%,) with the exception of Laos where the
only two reported cases have proved fatal [6]. Since data
collection ceased, at the end of 2011, until April 2013
there have been 13 further cases of H5N1 diagnosed in
Cambodia, with 11 fatalities, bringing the CFR to 87%
[6]. The 100% CFR of those under the age of 18 years also
contrasts with the findings of the study multi-country
study by Oner et al. which found children to have a lower
CFR than adults, 48.7% for those under 18 years and 28%
for those ≤5 years [26]. The median duration between
admission and death was shorter than that reported in
Indonesia, (one compared to three days), with more
patients dying on the day of admission (44% in Cambodia
versus 12% in Indonesia) [23]. This contrasts withThailand where fatal cases were hospitalised for a median
of six days before death [24]. The death of the majority of
patients within two days of hospitalisation suggests that,
like those patients in Indonesia, the Cambodian cases had
progressed to a stage when treatment was unlikely to
impact on clinical outcome [23].
Delays in the initiation of medical care and antiviral
therapy have been associated with increased severity of
influenza and undoubtedly contributed to the high fatality
rate of HPAI in Cambodia [26,27]. Barriers to accessing
health services have been reported to include physical
barriers such as distance, transport, waiting times; financial
barriers including direct and indirect costs; quality of care;
user knowledge and confidence; and sociocultural barriers,
including restrictions due to family circumstances and
reliance on traditional medicine [28]. The extent of the
distance travelled, including in two cases border crossings
to Vietnam, may reflect a distrust of public services and a
desire to avoid the associated user charges whether official
or under-the-table [28]. Indeed the Kantha Bopha
Children’s Hospitals attended by 10 of the 18 patients
(56%), is privately owned, funded by charitable donations
and provides completely free care of an anecdotally high
standard. Certainly patients or their caregivers were
motivated to travel since travel expenditure represents a
significant personal cost.
The mean cost-of-illness for HPAI in Cambodia amounted
to $299.69 per patient, with the majority of this cost,
85.0%, attributable to the medical provider costs particu-
larly those related to diagnostic testing (41.2%) and
pharmaceutical management (28.4%). The cost of HPAI in
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reported for dengue fever ($27 to $75 average cost per
case) and that of hospitalised cases of dengue and other
febrile illness ($36.20-$55.40) [29,30]. In the latter report
the direct medical costs were a lesser contributor, being
33-35% of the COI, with the balance attributable to non-
medical and indirect costs [29]. A notable factor in the
cost difference between HPAI and dengue relates to the
diagnostic testing and pharmaceutical management of
HPAI. In a pandemic situation PCR viral tests and
phenoytypic testing are unlikely to be feasible for all
patients due to patient load and therefore clinical diagnosis
is more likely. However laboratory diagnosis of HPAI may
be critical to receiving appropriate treatment, including use
of antiviral treatment. Improvements in the pharmaceutical
management of HPAI including the prompt use of
antivirals and reduced prescribing of corticosteroids
and antibiotics, also have potential to reduce the COI
and improve outcomes. There is also growing support
for various non antiviral generic drugs including statins,
which may reduce mortality from severe influenza through
mediation of the immune response and are widely available
at low cost [31-33].
Sensitivity analysis confirms the cost-of-illness for
HPAI falls dramatically to 4% of the average if hospital
care and the associated diagnostic testing and pharma-
ceuticals are excluded. In this scenario the majority
(86.6%) of costs are related to outpatient medicines. The
absence of hospital care for patients suffering H5N1 is a
likely scenario considering the limited health service
resources available in Cambodia and would undoubtedly
be associated with high rates of mortality. Conversely
the maximum care afforded by hospital admittance,
whilst undoubtedly reducing mortality, may result in an
almost three-fold increase in the COI, with the cost of
intensive care hospitalisation and pharmaceuticals being
major contributors.
Our research did not identify the payer of the costs
associated with illness and it is unknown how much of
the medical costs were out-of-pocket expenses for the
patients and their families, as compared to that subsidised
by the government, non-government organisations, insur-
ance or health equity funding. The patient or family
expenses $44.82 (or $55.77 including outpatient medical
costs) are considerable when they are considered with
respect to the average income of $237 per month and
prohibitive when compared to the average self-employed
income gained in agriculture of $61 per month [20].
Additionally these approximates likely underestimate
the cost of illness to a family as they may not include all
over-the-counter medications utilised, loss of income
related to care in the home, costs incurred for paying
others to fulfil labour commitments and other costs
incurred during hospitalisation, such as user charges forservices provided. Indeed it has been estimated that
two-thirds of total health expenditure in Cambodia is
from patients’ out-of-pocket spending at the time of
care, mainly for self-medication and private services [34].
As in other countries, catastrophic health expenditure has
been identified as a major cause of indebtedness and
destitution among the rural poor [34]. Access to free,
quality, tertiary hospital care at a provincial level will be
important to improving health care outcomes and reducing
the burden of HPAI.
Additional limitations of this study include: the use of
charges in place of costs for pharmaceuticals and diagnostic
tests which may overestimate the contribution of these
resources to the COI; and the lack of resource costs for
patients who travelled to Vietnam. While this study
represents all laboratory confirmed HPAI patients at the
time of data collection, the number of cases is low and
findings may differ from that during a serious pandemic
scenario, when health care services are likely to be
overwhelmed and incomes threatened. The true extent
of disease attributable to H5N1 in Cambodia is also
likely to be substantially higher than that described by
the identified cases. The majority of HPAI infections in
birds and humans occur in resource-poor areas where
access to appropriate health care and formal diagnoses
of H5N1 will be difficult to obtain. For these reasons it
is probable that a significant proportion of those who
contract the disease may go undetected, contributing to
selection bias for our sample. Indeed a meta-analysis of
studies, which assesses seroprevalence data for H5N1,
reports a 1-2% infection rate in exposed populations
[35]. The majority of mild or subclinical cases remain
unidentified, and the number of deaths from H5N1 is
also likely to be underestimated [35]. Thus, whilst the
cases reported in this article likely represent the most
severe infections with very poor clinical outcomes there
will be a greater burden of disease resulting from HPAI,
than that which has been captured by this data.
Conclusion
Cases of highly pathogenic avian influenza have been
characterised by young patient age, delays in hospitalisa-
tion, lack of adequate antiviral therapy, poor access to
mechanical ventilation and a high fatality rate. Many
patients died within a day of admission and may have
progressed to a stage where treatment was unlikely to
impact on clinical outcome. The substantial distances
travelled to the admitting hospital and the costs associated
with hospitalisation may have delayed patients and their
caregivers from seeking appropriate treatment. Indeed
the cost-of-illness for HPAI in Cambodia is relatively
high, compared to other febrile illnesses, and varies
considerably depending on the level of care received.
Medical provider costs, particularly diagnostic testing
Humphries-Waa et al. BMC Public Health 2013, 13:549 Page 8 of 9
http://www.biomedcentral.com/1471-2458/13/549and pharmaceutical costs were major contributors and
reduction of such could substantially reduce the total
cost of illness. Improved pharmaceutical management
including the prompt initiation of antivirals may not
only improve outcomes but also lower costs. Patient or
family costs are considerable and will have a marked
impact on poor families.
A highly pathogenic influenza outbreak in Cambodia
has the potential to be a catastrophic event both from a
loss of life and an economic perspective. Decision making
for pandemic influenza preparedness should consider the
potentially substantial cost of illness, both to the public
health system and to the patient or patient’s family, and
areas for improving patient care.
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